Experimental combo aims to boost Radiation's punch against returning lung tumors
NCT ID NCT04505267
First seen Nov 11, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose and understand side effects. About 34 participants will receive an injection of NBTXR3 directly into the tumor followed by targeted radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.